Application of orychophragmine D in preparation of medicine for inhibiting small intestine crypt epithelial cell ferroptosis
A technology of epithelial cells and ferroptosis, applied in the field of biomedicine, can solve problems such as narrow treatment time window, poor drug effect, and inhibition of spermatogenic cells, and achieve the effect of protecting radiation damage
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
preparation example Construction
[0024] The present invention has no special limitation on the preparation method of the zhugraine D, and the conventional preparation method in this field can be adopted. In a specific embodiment of the present invention, the preparation of the zhugraine D OV16 is preferably prepared according to the application number Prepared for the patent document of 201910175859.9.
[0025] In the present invention, the Erastin is a classical ferroptosis activator, acting on the mitochondrial voltage-dependent anion channel (VDAC) of various cell types. In order to establish the ferroptosis model of the rat intestinal crypt epithelial cell line IEC6, the present invention uses different concentrations of Erastin to treat the IEC6 cells, and observes the cell death induced by Erastin.
[0026] In the specific embodiment of the present invention, data analysis uses Graphpad Prism version 5.0 software (GraphPad software, Inc., La Jolla, CA, USA). All results are expressed as mean ± standard...
Embodiment 1
[0033] Erastin induces ferroptosis in rat intestinal crypt epithelial cell line IEC6
[0034] Cell viability was evaluated using CCK-8 (Dojindo Laboratories, KμMamoto, Japan) according to the kit instructions. IEC6 cells at 5 x 10 3 The concentration of cells (100 μL / well per well) was inoculated in a 96-well plate, and they were divided into two groups, Erastin treatment group and Fer-1 treatment group, with an average of 4 replicate wells in each group. Among them, the Erastin treatment group used Erastin (Tocris, Minneapolis, MN, USA) to treat the cells, and the final concentration of the medium was 0 μM, 0.25 μM, 0.5 μM, 1 μM, 2 μM, 5 μM, 10 μM; At the same time, the cells were treated with ferrostatin-1 (Fer-1) (Sigma-Aldrich, St Louis, MO, USA), and the final concentration of Fer-1 in the medium was 1 μM. Cells in each group were stored at 37°C, 5% CO 2 Culture in an incubator, detect cell viability after 24 hours, then add CCK-8 10 μL / well in each group, at 37°C, 5% ...
Embodiment 2
[0037] Zhugraine D (OV16) as an inhibitor of Erastin-induced ferroptosis in IEC6 cells
[0038] After digesting the IEC6 cells in the logarithmic growth phase, 5×10 3 The concentration of cells (100 μL per well) was inoculated in 96-well plates, and they were divided into three groups, namely Erastin treatment group, Fer-1 treatment group and OV16 treatment group. Among them, the Erastin treatment group was only treated with 2.5 μM Erastin, and the final concentration of the medium was 2.5 μM; the Fer-1 treatment group was treated with 2.5 μM Erastin plus 1 μM Fer-1; the OV16 treatment group was treated with 2.5 μM Erastin and 1, 5, Treatment with 10 μM zhugraine D (OV16) natural product compound. After each group was treated and reacted for 24 hours, the cell viability was evaluated using Cell Counting Kit-8 (CCK-8) according to the instructions (Dojindo Laboratories, Tokyo, Japan), and the results were as follows: figure 2 . All data are expressed as mean ± standard devi...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com